Samantha Semenkow
Stock Analyst at Citigroup
(1.71)
# 3,064
Out of 4,681 analysts
38
Total ratings
32%
Success rate
-9.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics | Initiates: Buy | $12 | $6.68 | +79.64% | 1 | Dec 2, 2024 | |
| BIOA BioAge Labs | Initiates: Buy | $45 | $16.70 | +169.46% | 1 | Oct 21, 2024 | |
| ARGX argenx SE | Maintains: Buy | $512 → $635 | $617.20 | +2.88% | 4 | Oct 17, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $7 → $8 | $2.42 | +231.26% | 2 | Aug 9, 2024 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $27 → $31 | $21.81 | +42.14% | 2 | Aug 9, 2024 | |
| SANA Sana Biotechnology | Maintains: Buy | $8 → $15 | $2.87 | +423.56% | 2 | Aug 9, 2024 | |
| SNSE Sensei Biotherapeutics | Reinstates: Buy | $4 | $0.54 | +640.47% | 2 | Jun 3, 2024 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $10 → $14 | $6.24 | +124.36% | 6 | May 22, 2024 | |
| PRME Prime Medicine | Upgrades: Buy | $10 | $3.40 | +194.12% | 2 | May 16, 2024 | |
| EDIT Editas Medicine | Maintains: Buy | $16 → $15 | $2.09 | +619.42% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $3.92 | +206.36% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $30 | $3.76 | +697.87% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $8 | $4.37 | +83.07% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $53.95 | +33.46% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $28.55 | +75.16% | 3 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $27.18 | +106.03% | 3 | Aug 9, 2023 |
Voyager Therapeutics
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $6.68
Upside: +79.64%
BioAge Labs
Oct 21, 2024
Initiates: Buy
Price Target: $45
Current: $16.70
Upside: +169.46%
argenx SE
Oct 17, 2024
Maintains: Buy
Price Target: $512 → $635
Current: $617.20
Upside: +2.88%
Allogene Therapeutics
Aug 9, 2024
Maintains: Buy
Price Target: $7 → $8
Current: $2.42
Upside: +231.26%
Catalyst Pharmaceuticals
Aug 9, 2024
Maintains: Buy
Price Target: $27 → $31
Current: $21.81
Upside: +42.14%
Sana Biotechnology
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $2.87
Upside: +423.56%
Sensei Biotherapeutics
Jun 3, 2024
Reinstates: Buy
Price Target: $4
Current: $0.54
Upside: +640.47%
Larimar Therapeutics
May 22, 2024
Maintains: Buy
Price Target: $10 → $14
Current: $6.24
Upside: +124.36%
Prime Medicine
May 16, 2024
Upgrades: Buy
Price Target: $10
Current: $3.40
Upside: +194.12%
Editas Medicine
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.09
Upside: +619.42%
Apr 8, 2024
Maintains: Buy
Price Target: $9 → $12
Current: $3.92
Upside: +206.36%
Apr 4, 2024
Maintains: Buy
Price Target: $26 → $30
Current: $3.76
Upside: +697.87%
Dec 8, 2023
Initiates: Neutral
Price Target: $8
Current: $4.37
Upside: +83.07%
Dec 8, 2023
Initiates: Buy
Price Target: $72
Current: $53.95
Upside: +33.46%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $28.55
Upside: +75.16%
Aug 9, 2023
Maintains: Buy
Price Target: $60 → $56
Current: $27.18
Upside: +106.03%